Regenetp (Regenetp) Valuation Rank

View and export this data going back to 1999. Start your Free Trial

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Regenetp Valuation Rank Related Terms

Thank you for viewing the detailed overview of Regenetp's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (Regenetp) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Executives

Peter A Cohen	director	40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg	director	1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague	officer: Chief Operating Officer	1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler	other: General Counsel	1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer	director	4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen	director	POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann	officer: Chief Financial Officer	C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson	officer: Chief Financial Officer	14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough	10 percent owner, other: Prior D&O within 90 days	4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann	director	1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson	director, officer: Chief Operating Officer	181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin	director	150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan	director	1943, ROSECREST DRIVE, OAKLAND CA 94602